Arenas, Maria DoloresRodelo-Haad, CristianPendón-Ruiz de Mier, M VictoriaRodriguez, Mariano2022-10-282022-10-282020-02-12Arenas MD, Rodelo-Haad C, Pendón-Ruiz de Mier MV, Rodriguez M. Control of hyperparathyroidism with the intravenous calcimimetic etelcalcetide in dialysis patients adherent and non-adherent to oral calcimimetics. Clin Kidney J. 2020 Feb 12;14(3):840-8462048-8505http://hdl.handle.net/10668/4299Background. In dialysis patients, non-adherence to oral cinacalcet adds complexity to the control of secondary hyperparathyroidism. The present study aims to evaluate the use of intravenous calcimimetic, etelcalcetide, in the control of secondary hyperparathyroidism in patients adherent and non-adherent to oral calcimimetics. Method. The Simplified Medication Adherence Questionnaire was used to identify non-adherence. Almost half of the patients were non-adherent to the treatment with cinacalcet. Twenty-five patients (15 non-adherent) were switched from cinacalcet to etelcalcetide and were followed-up monthly for 8 months. Results. Cinacalcet was discontinued for 1 week before the initiation of etelcalcetide. After this period, the serum PTH levels increased by2-fold in adherent patients, whereas it did not change in non-adherent patients suggesting that they were not taking the medication. Etelcalcetide progressively reduced serum parathyroid hormone (PTH) (mean 6 standard deviation) from 818 6 395 to 367 6 289 pg/mL (P< 0.001) in non-adherents, and from 496 6 172 to 228 6 111 pg/mL (P< 0.01) in adherent patients with a mean dose of 7.0 6 2.3 and 5.1 6 1.2 mg in non-adherent and in adherent patients, respectively. Etelcalcetide increased the percentage of patients with PTH on target from 28% to 58%. Patients with serum calcium <8.4 mg/dL increased from 8% to 40%, although they remained asymptomatic. The percent of patients with serum phosphate on target increased from 40% to 65%. Conclusion. The lack of adherence to cinacalcet is a possible cause of the apparent lack of response to oral calcimimetic.The use of etelcalcetide ensures compliance and control of secondary hyperparathyroidism in both non-adherent and adherent patients.enAn error occurred on the license name.Atribución-NoComercial 4.0 InternacionalAn error occurred getting the license - uri.http://creativecommons.org/licenses/by-nc/4.0/AdherenceCalciumCinacalcetEtelcalcetidePTHAdhesión celularCalcioHormona paratiroideaHiperparatiroidismo secundarioCumplimiento de la medicaciónPacientesDiálisisMedical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::HumansMedical Subject Headings::Chemicals and Drugs::Inorganic Chemicals::Calcium CompoundsMedical Subject Headings::Diseases::Endocrine System Diseases::Parathyroid Diseases::Hyperparathyroidism::Hyperparathyroidism, SecondaryMedical Subject Headings::Chemicals and Drugs::Hormones, Hormone Substitutes, and Hormone Antagonists::Hormones::Peptide Hormones::Parathyroid HormoneMedical Subject Headings::Psychiatry and Psychology::Behavior and Behavior Mechanisms::Behavior::Health Behavior::Patient Compliance::Medication AdherenceMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::QuestionnairesMedical Subject Headings::Chemicals and Drugs::Inorganic Chemicals::Phosphorus Compounds::Phosphorus Acids::Phosphoric Acids::PhosphatesMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Renal Replacement Therapy::Renal DialysisMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Chemistry Techniques, Analytical::DialysisMedical Subject Headings::Persons::Persons::Patientsresearch article33777366open access10.1093/ckj/sfaa0052048-8513PMC7986320